DelveInsight has launched a new report on “Diabetic Macular Edema – Market Insights, Epidemiology, and Market Forecast-2030”.
DelveInsight’s “Diabetic Macular Edema – Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Diabetic Macular Edema, historical and forecasted epidemiology as well as the Diabetic Macular Edema market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some of the key facts of the Diabetic Macular Edema Market Report:
As per a population-based study by Li et al. (2020), the prevalence of total diabetes defined by the WHO criteria increased from 9.7% in 2007 to 11.2% in 2017 among adults living in China. These findings indicate that diabetes is an important health problem in China. With growing diabetes cases, DME cases also increase in parallel.
Furthermore, In Japan, the total gender-specific diagnosed prevalent cases of DME were 50,717 for males and 36,726 for females, respectively in the year 2020.
According to DelveInsight’s analysis, in Japan, the age-specific diagnosed prevalent cases of DME for the age groups 18-44 years, 45-64 years, and ≥75 years were 12,565, 37,952, and 36,926, respectively, in the year 2020.
Key benefits of the report:
Diabetic Macular Edema market report covers a descriptive overview and comprehensive insight of the Diabetic Macular Edema Epidemiology and Diabetic Macular Edema market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
The Diabetic Macular Edema market report provides insights on the current and emerging therapies.
Diabetic Macular Edema market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Diabetic Macular Edema market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Diabetic Macular Edema market.
Diabetic Macular Edema Overview
Diabetic Macular Edema (DME) is triggered by Diabetic Retinopathy (DR), a well-known complication of diabetes. DR is the most prevalent diabetic eye disease and the leading cause of irreversible blindness in people in their working years in the developed and other developing countries.
Diabetic Macular Edema Market
The dynamics of the Diabetic Macular Edema market is anticipated to change in the coming years owing to the expected launch of emerging therapies such as Novartis, Roche, Kodiak Sciences, Adverum Biotechnologies, Graybug Vision, Ocuphire Pharma, Oxurion, Unity Biotechnology, and others during the forecasted period 2021-2030.
Learn more by requesting for sample @ Diabetic Macular Edema Market Landscape
Diabetic Macular Edema Pipeline Therapies and Key Companies
Beovu (brolucizumab): Novartis
KSI-301: Kodiak Sciences
ADVM022: Adverum Biotechnologies
GB-102: Graybug Vision
APX3330: Ocuphire Pharma
UBX1325: Unity Biotechnology
Diabetic Macular Edema Market Drivers
Increasing changes in lifestyle
Personalization of treatment
Addressing barriers to screening
Table of Contents
1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Diabetic Macular Edema Patient Share (%) Overview at a Glance
5. Diabetic Macular Edema Market Overview at a Glance
6. Diabetic Macular Edema Disease Background and Overview
7. Diabetic Macular Edema Epidemiology and Patient Population
8. Country-Specific Patient Population of Diabetic Macular Edema
9. Diabetic Macular Edema Current Treatment and Medical Practices
10. Unmet Needs
11. Diabetic Macular Edema Emerging Therapies
12. Diabetic Macular Edema Market Outlook
13. Country-Wise Diabetic Macular Edema Market Analysis (2017–2030)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
18. Diabetic Macular Edema Report Methodology
19. DelveInsight Capabilities
21. About DelveInsight
Click here to read more about Diabetic Macular Edema Market Outlook 2030
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States